- Last week, PropThink reported on Elan’s (NYSE:ELN) potential to fall as a result of bapineuzumab failures and disappearing buy-out speculation. We cited an article from … Continue Reading
Read nowQuick Picks - After a run-up to $1.44 last week, Chelsea Therapeutics (NASDAQ:CHTP) has been giving up gains as momentum ebbed and the company released no major updates … Continue Reading
Read nowLong Ideas - The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will meet this Thursday to discuss the NDA for Cornerstone Therapeutics’ (NASDAQ:CRTX) lixivaptan for the treatment … Continue Reading
Read nowLong Ideas - Amarin (NASDAQ:AMRN) announced on Monday that it is unlikely Vascepa’s regulatory exclusivity will be listed in the August Orange Book supplement, due out in mid-September. … Continue Reading
Read nowLong Ideas - Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) are rebounding from late losses on Monday, up 50% in premarket trading after the company announced an increase in the … Continue Reading
Read nowLong Ideas - Analysts and investors are refocusing on the opportunity for Pain Therapeutics’ (NASDAQ:PTIE) lead drug candidate, Remoxy. Remoxy is an extended-release formulation of the widely used … Continue Reading
Read nowMost Popular - Cell Therapeutics (NASDAQ:CTIC) closed 10% higher on Monday in anticipation of positive trial data from management at the Rodman & Renshaw Conference in NYC. The … Continue Reading
Read now